AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16539815 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlogenzym (PE)
Number of subjects: 90
Study 16539815 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (DC)
Number of subjects: 90
Study 14607210 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 14607210 — intervention group
Group type: COMPARATOR
Intervention: B-type natriuretic peptide testing
Number of subjects: 0
Study 14607210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 14607210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran plus aspirin
Number of subjects: 0
Study 10653825 — intervention group
Group type: EXPERIMENTAL
Intervention: (192)Ir
Number of subjects: 55
Study 10653825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal response to electrolyte changes and water loss in patients with heat exhaustion
Number of subjects: 0
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels in patients with heat exhaustion
Number of subjects: 0
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (ADH) levels in patients with heat exhaustion
Number of subjects: 0
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH concentration in patients with heat exhaustion
Number of subjects: 0
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH concentrations in patients with heat exhaustion
Number of subjects: 0
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: GH concentration in patients with heat exhaustion
Number of subjects: 0
Study 7645364 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone concentration in patients with heat exhaustion
Number of subjects: 0
Study 2518864 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 274
Study 2518864 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg)
Number of subjects: 274
Study 782159 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 20
Study 782159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31291710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination 2 weeks before chemotherapy (Arm A)
Number of subjects: 92
Study 31291710 — intervention group
Group type: COMPARATOR
Intervention: Vaccination on the first day of chemotherapy (Arm B)
Number of subjects: 92
Study 31044546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 5000
Study 27910086 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at a higher haemoglobin threshold of 90 g/l
Number of subjects: 998
Study 27910086 — intervention group
Group type: COMPARATOR
Intervention: Transfusion at a lower haemoglobin threshold of 70 g/l
Number of subjects: 998
Study 25733335 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised major purgative decoction (100 ml infused through the decompression tube, three times daily)
Number of subjects: 31
Study 25733335 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.5 mg by muscle injection, twice daily)
Number of subjects: 31
Study 24667866 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion (30% soybean oil, 30% medium-chain triacylglycerol, 25% olive oil, 15% fish oil)
Number of subjects: 96
Study 24667866 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion
Number of subjects: 96
Study 24667866 — intervention group
Group type: COMPARATOR
Intervention: Pure soybean oil emulsion (control)
Number of subjects: 96
Study 24667866 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent lipid emulsion and Pure soybean oil emulsion
Number of subjects: 96
Study 22017727 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-worn device that offers vibration when in supine position
Number of subjects: 30
Study 22017727 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-worn device in ON modus
Number of subjects: 30
Study 19262464 — intervention group
Group type: EXPERIMENTAL
Intervention: Refill adherence <40%
Number of subjects: 192
Study 19262464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription label reading skills
Number of subjects: 192
Study 19262464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate health literacy
Number of subjects: 192
Study 17467237 — intervention group
Group type: EXPERIMENTAL
Intervention: Novalac-IT
Number of subjects: 93
Study 17467237 — intervention group
Group type: COMPARATOR
Intervention: 20% strengthened formula (S group)
Number of subjects: 93
Study 16138563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of angiotensin receptor blockers, beta-blockers, or thiazide diuretics in addition to benidipine hydrochloride with response-dependent dose titration
Number of subjects: 3000
Study 16138563 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3000
Study 12466030 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/d
Number of subjects: 11
Study 12466030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9642886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) training
Number of subjects: 202
Study 9642886 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive dynamic therapy (SE) training
Number of subjects: 202
Study 9642886 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling training
Number of subjects: 202
Study 9642886 — intervention group
Group type: COMPARATOR
Intervention: Drug counseling training
Number of subjects: 202
Study 9545905 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental resin-modified glass ionomer cement (K-512 = Fuji III LC)
Number of subjects: 17
Study 9545905 — intervention group
Group type: COMPARATOR
Intervention: Light-cured resin-based sealant (Delton Opaque)
Number of subjects: 17
Study 2021339 — intervention group
Group type: EXPERIMENTAL
Intervention: Level I axillary involvement
Number of subjects: 135
Study 2021339 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II axillary involvement
Number of subjects: 135
Study 2021339 — intervention group
Group type: EXPERIMENTAL
Intervention: Level III axillary involvement
Number of subjects: 135
Study 2021339 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of positive nodes (one to three)
Number of subjects: 135
Study 2021339 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of positive nodes (four or more)
Number of subjects: 135
Study 6759139 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg carprofen daily in 3 doses for 21 days
Number of subjects: 50
Study 6759139 — intervention group
Group type: COMPARATOR
Intervention: 150 mg diclofenac-Na daily in 3 doses for 21 days
Number of subjects: 50
Study 31435005 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary phosphorus excretion
Number of subjects: 622
Study 31435005 — intervention group
Group type: EXPERIMENTAL
Intervention: Added phosphorus intake
Number of subjects: 622
Study 31435005 — intervention group
Group type: EXPERIMENTAL
Intervention: Total phosphorus intake
Number of subjects: 622
Study 30554434 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of handwritten prescriptions
Number of subjects: 580
Study 30554434 — intervention group
Group type: COMPARATOR
Intervention: External assessment of handwritten prescriptions
Number of subjects: 580
Study 27765610 — intervention group
Group type: EXPERIMENTAL
Intervention: tPCS
Number of subjects: 48
Study 27765610 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tPCS and tDCS
Number of subjects: 48
Study 27765610 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 48
Study 27765610 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study 26074314 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 1.8 g/day
Number of subjects: 50
Study 26074314 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA 1.8 g/day
Number of subjects: 50
Study 26074314 — intervention group
Group type: COMPARATOR
Intervention: Olive oil 6.0 g/day
Number of subjects: 50
Study 23710688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day (bulimic patients)
Number of subjects: 33
Study 23710688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day (non-bulimic patients)
Number of subjects: 33
Study 23710688 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 21481486 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS
Number of subjects: 264
Study 21481486 — intervention group
Group type: COMPARATOR
Intervention: Non-EBUS
Number of subjects: 264
Study 21481486 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy and brushing
Number of subjects: 264
Study 21481486 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing added to biopsy
Number of subjects: 264
Study 21481486 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing or TBNA
Number of subjects: 264
Study 19224481 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antigen stimulation (low concentration 1:100 and high concentration 1:40)
Number of subjects: 0
Study 19224481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 17205469 — intervention group
Group type: COMPARATOR
Intervention: Standard melarsoprol therapy (3 series of 3.6 mg/kg/day iv for 3 days, with 7-day breaks between series)
Number of subjects: 278
Study 17205469 — intervention group
Group type: COMPARATOR
Intervention: 10-day incremental-dose melarsoprol therapy (0.6 mg/kg iv on day 1, 1.2 mg/kg iv on day 2, and 1.8 mg/kg iv on days 3-10)
Number of subjects: 278
Study 17205469 — intervention group
Group type: COMPARATOR
Intervention: Nifurtimox monotherapy for 14 days (5 mg/kg orally 3 times per day)
Number of subjects: 278
Study 17205469 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive 10-day melarsoprol-nifurtimox combination therapy (0.6 mg/kg iv melarsoprol on day 1, 1.2 mg/kg iv melarsoprol on day 2, and 1.2 mg/kg/day iv melarsoprol combined with oral 7.5 mg/kg nifurtimox twice a day on days 3-10)
Number of subjects: 278
Study 17205469 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens (including monotherapy)
Number of subjects: 278
Study 17205469 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 278
Study 14997270 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (40-60% HRR)
Number of subjects: 84
Study 14997270 — intervention group
Group type: COMPARATOR
Intervention: Light intensity exercise (10-20% HRR)
Number of subjects: 84
Study 14997270 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 84
Study 11249916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 9609370 — intervention group
Group type: EXPERIMENTAL
Intervention: xenogenic bovine bone
Number of subjects: 8
Study 9609370 — intervention group
Group type: EXPERIMENTAL
Intervention: demineralized freeze-dried bone (DFDBA)
Number of subjects: 8
Study 9609370 — intervention group
Group type: EXPERIMENTAL
Intervention: human bone morphogenetic proteins in an osteocalcein/osteonectin carrier (hBMP/NCP)
Number of subjects: 8
Study 9609370 — intervention group
Group type: COMPARATOR
Intervention: micro screws with bovine bone
Number of subjects: 8
Study 9609370 — intervention group
Group type: COMPARATOR
Intervention: micro screws with DFDBA
Number of subjects: 8
Study 9609370 — intervention group
Group type: COMPARATOR
Intervention: micro screw with intra-oral autologous bone
Number of subjects: 8
Study 7663574 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym (WE)
Number of subjects: 28
Study 7663574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7663574 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study 2646258 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional preoperative radiotherapy (5000 cGy/25 Fx/5 wk) with hyperthermia (HT) given once or twice weekly during the 5 week course
Number of subjects: 0
Study 2646258 — intervention group
Group type: EXPERIMENTAL
Intervention: Requiring ≥ 1/3 of treatments to satisfy the discriminant equation
Number of subjects: 0
Study 237519 — intervention group
Group type: EXPERIMENTAL
Intervention: Medazepam 10 mg
Number of subjects: 0
Study 237519 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 237519 — intervention group
Group type: COMPARATOR
Intervention: Dummy capsule (placebo)
Number of subjects: 0
Study 30656889 — intervention group
Group type: EXPERIMENTAL
Intervention: Precise hepatectomy
Number of subjects: 116
Study 30656889 — intervention group
Group type: COMPARATOR
Intervention: Conventional hepatectomy
Number of subjects: 116
Study 27862806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance (FG)
Number of subjects: 450
Study 27862806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined guidance (CG)
Number of subjects: 450
Study 27862806 — intervention group
Group type: COMPARATOR
Intervention: Total ultrasonographic guidance (USG)
Number of subjects: 450
Study 27862806 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study 25361657 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide (spasmolytic)
Number of subjects: 100
Study 25361657 — intervention group
Group type: COMPARATOR
Intervention: Control (no spasmolytic)
Number of subjects: 100
Study 23887198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch (5%)
Number of subjects: 21
Study 23887198 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 21
Study 23887198 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline intraepidermal nerve fiber density
Number of subjects: 21
Study 21981451 — intervention group
Group type: COMPARATOR
Intervention: Control condition of continuous postocclusion hyperaemia
Number of subjects: 10
Study 21981451 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds of reactive hyperaemia
Number of subjects: 10
Study 21981451 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 seconds of reactive hyperaemia
Number of subjects: 10
Study 21981451 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 seconds of reactive hyperaemia
Number of subjects: 10
Study 21981451 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 seconds of reactive hyperaemia (second cuff release)
Number of subjects: 10
Study 21981451 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 seconds of reactive hyperaemia (second cuff release)
Number of subjects: 10
Study 21981451 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds of reactive hyperaemia (second cuff release)
Number of subjects: 10
Study 18482418 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone (50 mg/day)
Number of subjects: 169
Study 18482418 — intervention group
Group type: EXPERIMENTAL
Intervention: acamprosate (1998 mg/day)
Number of subjects: 169
Study 18482418 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study 16528138 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 323
Study 16528138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg/day)
Number of subjects: 323
Study 16528138 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 323
Study 16528138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 323
Study 16528138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 323
Study 14567887 — intervention group
Group type: COMPARATOR
Intervention: Cetrorelix (GnRH antagonist) 3 mg
Number of subjects: 671
Study 14567887 — intervention group
Group type: EXPERIMENTAL
Intervention: Decapeptyl Retard (GnRH agonist) 3.75 mg
Number of subjects: 671
Study 10877165 — intervention group
Group type: EXPERIMENTAL
Intervention: Td-IPV
Number of subjects: 301
Study 10877165 — intervention group
Group type: COMPARATOR
Intervention: Td
Number of subjects: 301
Study 9351406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofer (27 mg elemental iron with heme and non-heme iron)
Number of subjects: 90
Study 9351406 — intervention group
Group type: EXPERIMENTAL
Intervention: Collets jern med vitamin C (27 mg elemental iron with non-heme iron)
Number of subjects: 90
Study 9351406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7692166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 0
Study 7692166 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 0
Study 3549869 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150-300 mg/day)
Number of subjects: 99
Study 3549869 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150-300 mg/day)
Number of subjects: 99
Study 3549869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose desipramine (50 mg)
Number of subjects: 99
Study 3549869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amitriptyline (50 mg)
Number of subjects: 99
Study 31015198 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 64
Study 31015198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29486131 — intervention group
Group type: EXPERIMENTAL
Intervention: AEE (Agrimonia eupatoria L. aqueous extract) - 2 capsules twice a day for 8 weeks
Number of subjects: 69
Study 29486131 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 2 capsules twice a day for 8 weeks
Number of subjects: 69
Study 29486131 — intervention group
Group type: EXPERIMENTAL
Intervention: AEE (Agrimonia eupatoria L. aqueous extract)
Number of subjects: 69
Study 26747264 — intervention group
Group type: EXPERIMENTAL
Intervention: Double reading with consensus and arbitration
Number of subjects: 57157
Study 26747264 — intervention group
Group type: COMPARATOR
Intervention: Single reading with first reader only
Number of subjects: 57157
Study 24655407 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fish oil fat emulsion-based parenteral nutrition
Number of subjects: 48
Study 24655407 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (Control)
Number of subjects: 48
Study 22001664 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning with the word 'sting'
Number of subjects: 100
Study 22001664 — intervention group
Group type: COMPARATOR
Intervention: Warning with the word 'beware'
Number of subjects: 100
Study 20823345 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement
Number of subjects: 45
Study 20823345 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (euthyroid)
Number of subjects: 45
Study 17372696 — intervention group
Group type: EXPERIMENTAL
Intervention: Indium chloride adsorbed onto activated charcoal, entrapped in cellulose acetate polymer melt; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15783255 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic agents
Number of subjects: 0
Study 15783255 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12063705 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Number of subjects: 50
Study 12063705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 50
Study 12063705 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 12063705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups
Number of subjects: 50
Study 9466024 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 femoral nerve block
Number of subjects: 40
Study 9466024 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 40
Study 7893018 — intervention group
Group type: EXPERIMENTAL
Intervention: High infusion (20 mL/kg)
Number of subjects: 200
Study 7893018 — intervention group
Group type: COMPARATOR
Intervention: Low infusion (2 mL/kg)
Number of subjects: 200
Study 2761685 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg hydrocortisone
Number of subjects: 45
Study 2761685 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 45
Study 2761685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29304768 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting vaginal Lactobacillus rhamnosus BMX 54 administration (6 months)
Number of subjects: 117
Study 29304768 — intervention group
Group type: COMPARATOR
Intervention: Short-term vaginal Lactobacillus implementation (3 months)
Number of subjects: 117
Study 27076041 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon α‐2b (IFN)
Number of subjects: 602
Study 27076041 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 602
Study 27076041 — intervention group
Group type: COMPARATOR
Intervention: High YKL‐40 expression in macrophages in lymph node metastases
Number of subjects: 602
Study 27076041 — intervention group
Group type: COMPARATOR
Intervention: Increases in YKL‐40 during follow-up
Number of subjects: 602
Study 25659520 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg rectal morphine
Number of subjects: 15
Study 25659520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22949583 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic feedback (GF) plus standard behavioral counseling (BC) for smoking cessation
Number of subjects: 36
Study 22949583 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral counseling (BC) without genetic feedback (GF)
Number of subjects: 36
Study 20580572 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (inspired concentration between 1.0% and 2.5%)
Number of subjects: 45
Study 20580572 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5 to 3.5 mg/kg/h)
Number of subjects: 45
Study 18167121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) 5 x 10(9) colony-forming units twice daily for 4-6 weeks before delivery and 6 months post-natal
Number of subjects: 68
Study 18167121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 18167121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro stimulation with LGG
Number of subjects: 68
Study 18167121 — intervention group
Group type: COMPARATOR
Intervention: Maternal and neonatal mononuclear cells (MC)
Number of subjects: 68